Advanced Research in Hematopoietic Stem Cells and Transplantation
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Gene and Cell Therapy".
Deadline for manuscript submissions: closed (28 February 2021) | Viewed by 445
Special Issue Editor
Interests: transplantation medicine; molecular biology in leukemia; transplantation immunology; cancer immunotherapy; tumor microenvironment
Special Issue Information
Dear Colleagues,
The special field of acute leukemia is gathering much interest due to the expanded results of fascinating and novel new trials using many ‘first-in-class’ anti-leukemic agents with multiple modalities such as antibodies, cells, vaccines, and new immunomodulators. These developments have emerged from 50 years of research devoted to hematopoietic stem cells and even discoveries of cross-talk between veiled marrow microenvironment.
However, we have still a long way to go before we can overcome the hurdle of heterogeneities of molecular profiling in terms of measurable residual disease (MRD) for each patient with rapidly progressing leukemia to give more accurate guidance to therapeutic approaches at multiple time points or real-time in clinical settings.
On the other hand, outcomes for younger patients with AML are improving substantially due to the outstanding results of alternative donor transplantations, including unrelated, haploidentical, and cord blood sources. However, these are not a complete success yet, specifically for elderly patients, despite increasing numbers of transplants being performed for acute leukemia in older patients (greater than 60 or even 70 years old).
Therefore, we invite authors to submit original research and review articles that focus on recent trends of translational and/or clinical development based on the advanced research in hematopoietic stem cells and transplantation related issues. Potential topics include, but are not limited to the following:
- Hematopoietic stem cells and marrow microenvironment with new therapeutic strategies;
- Novel approaches of alternative donor transplantation for acute leukemia;
- Combined trials in hematopoietic stem cell transplantation (HSCT) and the role of MRD by novel concepts;
- Anti-leukemic immunotherapies with or without HSCT;
- Molecular biology of acute leukemia by using modern techniques of cellular analysis or related tools.
- Hematopoietic stem cells and marrow microenvironment with new therapeutic strategies;
- Novel approaches of alternative donor transplantation for acute leukemia;
- Combined trials in hematopoietic stem cell transplantation (HSCT) and the role of MRD by novel concepts;
- Anti-leukemic immunotherapies with or without HSCT;
- Molecular biology of acute leukemia by using modern techniques of cellular analysis or related tools.
Dr. Hee-Je Kim
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- acute leukemia
- AML
- marrow microenvironment
- hematopoietic stem cells
- alternative donor transplantation
- measurable residual disease
- immunotherapy
- molecular biology
- cellular analysis
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
